Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.386 CHF
−516.93 M CHF
508.80 M CHF
89.64 M
About Ultragenyx Pharmaceutical Inc.
Sector
Industry
CEO
Emil D. Kakkis
Website
Headquarters
Novato
Founded
2010
ISIN
US90400D1081
FIGI
BBG00LVGHPH1
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of UP0 is 24.746 CHF — it has decreased by −38.92% in the past 24 hours. Watch Ultragenyx Pharmaceutical, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Ultragenyx Pharmaceutical, Inc. stocks are traded under the ticker UP0.
We've gathered analysts' opinions on Ultragenyx Pharmaceutical, Inc. future price: according to them, UP0 price has a max estimate of 102.20 CHF and a min estimate of 27.15 CHF. Watch UP0 chart and read a more detailed Ultragenyx Pharmaceutical, Inc. stock forecast: see what analysts think of Ultragenyx Pharmaceutical, Inc. and suggest that you do with its stocks.
UP0 stock is 63.73% volatile and has beta coefficient of 1.05. Track Ultragenyx Pharmaceutical, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ultragenyx Pharmaceutical, Inc. there?
Today Ultragenyx Pharmaceutical, Inc. has the market capitalization of 2.45 B, it has decreased by −21.79% over the last week.
Yes, you can track Ultragenyx Pharmaceutical, Inc. financials in yearly and quarterly reports right on TradingView.
Ultragenyx Pharmaceutical, Inc. is going to release the next earnings report on Nov 4, 2025. Keep track of upcoming events with our Earnings Calendar.
UP0 earnings for the last quarter are −0.93 CHF per share, whereas the estimation was −1.03 CHF resulting in a 9.81% surprise. The estimated earnings for the next quarter are −0.98 CHF per share. See more details about Ultragenyx Pharmaceutical, Inc. earnings.
Ultragenyx Pharmaceutical, Inc. revenue for the last quarter amounts to 132.10 M CHF, despite the estimated figure of 128.54 M CHF. In the next quarter, revenue is expected to reach 133.35 M CHF.
UP0 net income for the last quarter is −91.20 M CHF, while the quarter before that showed −133.74 M CHF of net income which accounts for 31.81% change. Track more Ultragenyx Pharmaceutical, Inc. financial stats to get the full picture.
No, UP0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 8, 2025, the company has 1.29 K employees. See our rating of the largest employees — is Ultragenyx Pharmaceutical, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ultragenyx Pharmaceutical, Inc. EBITDA is −372.62 M CHF, and current EBITDA margin is −89.33%. See more stats in Ultragenyx Pharmaceutical, Inc. financial statements.
Like other stocks, UP0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ultragenyx Pharmaceutical, Inc. stock right from TradingView charts — choose your broker and connect to your account.